SRPT - サレプタ・セラピュ―ティックス （Sarepta Therapeutics Inc.）SRPTのニュース
This Is What Whales Are Betting On Sarepta Therapeutics 2023/05/03 19:02:09 Benzinga
Someone with a lot of money to spend has taken a bullish stance on Sarepta Therapeutics (NASDAQ: SRPT ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with SRPT, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 14 uncommon options trades for Sarepta Therapeutics. This isn''t normal. The overall sentiment of these big-money traders is split between 57% bullish and 42%, bearish. Out of all of the special options we uncovered, 6 are puts, for a total amount of $449,130, and 8 are calls, for a total amount of $470,774. What''s The Price Target? Taking into … Full story available on Benzinga.com
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript 2023/05/03 04:00:25 The Motley Fool
SRPT earnings call for the period ending March 31, 2023.
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript 2023/05/03 00:52:02 Seeking Alpha
Sarepta Therapeutics, Inc. (NASDAQ:NASDAQ:SRPT) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsMary Jenkins – Associate Director-Investor RelationsDoug Ingram –…
Sarepta Therapeutics Q1 Loss Increases, but beats estimates 2023/05/02 20:36:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company''s earnings came in at -$516.76 mill…
Sarepta Therapeutics: Q1 Earnings Snapshot 2023/05/02 20:23:23 WTOP
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Tuesday reported a loss of $516.8 million…
Buy - Sarepta Therapeutics Receives New Coverage from Analysts at Citigroup 2023/04/05 08:01:12 Business Mag
Citigroup began coverage on shares of Sarepta Therapeutics in a research report report published on Tuesday, The Fly reports. The brokerage issued a buy rating and a $179.00…
Sarepta Therapeutics (NASDAQ:SRPT) Receives New Coverage from Analysts at Citigroup 2023/04/05 07:58:41 The AM Reporter
Citigroup began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) in a research report report published on Tuesday, The Fly reports. The brokerage issued a buy rating and a $179.00 price objective on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. Oppenheimer decreased their price objective […]
Sarepta gains as Citi issues Buy despite AdCom for gene therapy 2023/04/04 12:12:59 Seeking Alpha
Sarepta Therapeutics (SRPT) shares gained Tuesday after Citi initiated its coverage with a Buy citing a compelling setup ahead of an FDA AdCom meeting. Read more here.
FDA Hands Sarepta A Positive Catalyst 2023/03/28 11:30:00 Seeking Alpha
Sarepta Therapeutics'' gene therapy has a novel mechanism for increasing a different type of dystrophin to treat a rare disease. Read more on FDA''s recent decision.
SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT 2023/03/25 18:30:00 Kwhen Finance
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday 2023/03/01 15:18:41 Benzinga
U.S. stocks traded lower, with the Dow Jones … Full story available on Benzinga.com
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy 2023/03/01 15:01:22 Investor''s Business Daily
Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today? 2023/03/01 14:49:58 InvestorPlace
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.